The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Lung cancer in China: current and prospect
Abstract
Purpose of review: To describe the current status of lung cancer in China, including incidence, prevention, molecular testing and treatment. Recent findings: Lung cancer presents a major public health issue and an enormous burden on society in China, because of its increasing incidence and high mortality. Several distinct gene profiles were associated with lung cancer in China: high EGFR mutation rate, low KRAS mutation rate and more comorbidity of HBV infection. Thus, local Chinese Society of Clinical Oncology Guidelines with more consideration of drug accessibility, regional development differences were highly recommended for clinical practice. For treatment, targeted therapy has achieved fruitful progress. Immunotherapy in China was a little bit lag behind previously and now there is a surge of immunotherapeutic drugs under investigation. For future, more preventive strategies and more trials considering chrematistics of Chinese lung cancer are needed. Summary: There are achievements and shortcomings for lung cancer prevention and treatment in China. More work considering distinct characteristic of lung caner in China are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081
Self-citationCouzin-Frankel, J. (2013) · Science · doi:10.1126/science.342.6165.1432 · Cited by 2,051 · cited 12×
“The ORIENT-11 trial investigating the combination of sintilimab with pemetrexed/ carboplatin as first-line therapy for locally advanced or metastatic nonsquamous NSCLC showed significantly prolonged PFS (8.9 vs. 5.0, hazard ratio¼0.482) and higher ORR (51.9 vs. 29.8”
BackgroundInfluentialGettinger, S., Horn, L., Jackman, D., Spigel, D., Antonia, S., Hellmann, M., Powderly, J., Heist, R., Sequist, L. V., Smith, D. C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.0412 · Cited by 738
[Report of cancer epidemiology in China, 2015].
Zheng, R., Sun, K., Zhang, S., Zeng, H., Zou, X., Chen, R., Gu, X., Wei, W., & He, J. (2019) · PubMed · doi:10.3760/cma.j.issn.0253-3766.2019.01.005 · Cited by 643
Epidemiology of lung cancer in China
Cao, M., & Chen, W. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.12916 · Cited by 471
Epidemiology of lung cancer in China
Chen, W., Zheng, R., Zeng, H., & Zhang, S. (2015) · Thoracic Cancer · doi:10.1111/1759-7714.12169 · Cited by 428
Shi, Y., Zhang, L., Liu, X., Zhou, C., Zhang, L., Zhang, S., Wang, D., Li, Q., Qin, S., Hu, C., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70355-3 · Cited by 422
Self-citationZhou, C., Wu, Y.-L., Chen, G., Liu, X., Zhu, Y., Lu, S., Feng, J., He, J., Han, B., Wang, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4424 · Cited by 372
Self-citationWu, Y.-L., Lu, S., Cheng, Y., Zhou, C., Wang, J., Mok, T., Zhang, L., Tu, H.-Y., Wu, L., Feng, J., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.01.006 · Cited by 357
Self-citation
Metadata
- Authors
- Wu, F., Wang, L., & Zhou, C.
- Venue
- Current Opinion in Oncology
- Published
- 2020-11-05
- Volume
- 33
- Issue
- 1
- Pages
- 40-46
- ISSN
- 1040-8746 (ISSN-L)
- 1531-703X
- OpenAlex
- W3104684621
- Cited by
- 309
- References
- 27
- FWCI
- 18.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lung cancer in China: current and prospect. https://app.cochat.ai/papers/10.1097/cco.0000000000000703
- The paper
- Wu, F., Wang, L., & Zhou, C. (2021). Lung cancer in China: current and prospect. Current Opinion in Oncology. https://doi.org/10.1097/cco.0000000000000703
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.